Vertex Pharmaceuticals (NASDAQ:VRTX) had its price target increased by Oppenheimer from $175.00 to $190.00 in a report published on Thursday, January 4th. The firm currently has an outperform rating on the pharmaceutical company’s stock.
Several other equities research analysts also recently weighed in on the company. Needham & Company LLC reaffirmed a buy rating and set a $195.00 price target on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. HC Wainwright reaffirmed a hold rating and set a $85.00 price target on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. Maxim Group reaffirmed a buy rating and set a $195.00 price target on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. Cowen reaffirmed a buy rating and set a $200.00 price target on shares of Vertex Pharmaceuticals in a report on Monday, December 11th. Finally, Vetr downgraded Vertex Pharmaceuticals to a sell rating in a report on Thursday, September 21st. One analyst has rated the stock with a sell rating, three have given a hold rating, twenty-five have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $175.89.
Shares of Vertex Pharmaceuticals (NASDAQ VRTX) traded up $1.02 during trading on Thursday, reaching $158.40. 950,600 shares of the company’s stock traded hands, compared to its average volume of 1,549,512. The stock has a market capitalization of $39,850.00, a price-to-earnings ratio of 203.08, a P/E/G ratio of 1.84 and a beta of 1.58. Vertex Pharmaceuticals has a one year low of $79.78 and a one year high of $167.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.28 and a quick ratio of 3.14.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.04 by $0.49. The business had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The company’s revenue for the quarter was up 39.7% compared to the same quarter last year. During the same period last year, the firm posted $0.16 earnings per share. sell-side analysts predict that Vertex Pharmaceuticals will post 0.76 earnings per share for the current year.
In other Vertex Pharmaceuticals news, Director Sangeeta N. Bhatia sold 10,753 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $156.00, for a total value of $1,677,468.00. Following the completion of the sale, the director now owns 14,706 shares in the company, valued at approximately $2,294,136. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jeffrey M. Leiden sold 125,000 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $141.35, for a total value of $17,668,750.00. Following the completion of the sale, the chief executive officer now owns 237,407 shares of the company’s stock, valued at approximately $33,557,479.45. The disclosure for this sale can be found here. In the last quarter, insiders have sold 354,214 shares of company stock valued at $51,154,692. 1.80% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. grew its holdings in Vertex Pharmaceuticals by 15.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock valued at $127,000 after buying an additional 132 shares during the period. FNY Partners Fund LP lifted its stake in shares of Vertex Pharmaceuticals by 900.0% in the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock valued at $128,000 after purchasing an additional 900 shares in the last quarter. Smithfield Trust Co. acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $135,000. FNY Managed Accounts LLC acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $162,000. Finally, Fuller & Thaler Asset Management Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $198,000. Institutional investors own 93.09% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Oppenheimer Raises Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $190.00” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://ledgergazette.com/2018/01/12/vertex-pharmaceuticals-vrtx-price-target-raised-to-190-00-at-oppenheimer.html.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.